The plasma form of PAF-AH [PAF (platelet-activating factor) acetylhydrolase; also known as LpPLA 2 (lipopoproteinassociated phospholipase A 2 ), PLA 2 G7] catalyses the release of sn-2 fatty acyl residues from PAF, oxidatively fragmented phospholipids, and esterified isoprostanes. The plasma levels of this enzyme vary widely among mammalian species, including mice and humans, but the mechanisms that account for these differences are largely unknown. We investigated the basis for these variations using molecular and biochemical approaches. We identified an N-terminal domain that played key roles in the determination of steady-state expression levels. The mouse N-terminal domain robustly enhanced protein expression levels, possibly owing to its ability to adopt a globular conformation that is absent in the human protein. We investigated the mechanism(s) whereby the N-terminal stretch modulated PAF-AH levels and found that differential expression was not due to variations in the efficiency of transcription, translation, or mRNA stability. Studies designed to evaluate the ability of precursor forms of PAF-AH to mature to fully active proteins indicated that the N-terminal end of human and mouse PAF-AH played important and opposite roles in this process. These domains also modulated the levels of expression of an unrelated polypeptide by affecting the stability of precursor forms of the protein. These studies provide insights that contribute to our understanding of the molecular features and mechanisms that contribute to differential expression of plasma PAF-AH in mammals.
INTRODUCTION

PAF-AH [PAF (platelet-activating factor; 1-O-alkyl-2-acetyl-
sn-glycero-3-phosphocholine) acetylhydrolase; also known as PLA 2 G7, LpPLA 2 (lipopoprotein-associated phospholipase A 2 )] is an unusual phospholipase A 2 that catalyses the hydrolysis of a wide range of biologically-active phospholipids such as PAF [1] , OxPLs (oxidatively-fragmented phospholipids) [2] , esterified isoprostanes [3] , and hydroxyl fatty acyl phospholipids [4] . PAF-AH is expressed and secreted primarily by cells of the haematopoietic system and has been reported to play essential roles in inflammation, vascular disorders, anaphylaxis and bowel diseases [5] . Multiple independent studies have unequivocally demonstrated that circulating plasma PAF-AH levels are positively associated with coronary heart disease and stroke (see [6] for a recent review), leading to the proposition that this parameter can be used to assess the future risk of cardiovascular events [7] . Although these observations have been, in general, uniform, the contribution of this enzyme to physiological and disease processes continues to be controversial [8] .
It has been known for many years that mouse and human plasma express vastly different levels of PAF-AH activity. We recently conducted a study in which we surveyed plasma PAF-AH levels in various mammalian species, and found that basal PAF-AH activity was significantly lower (10-fold) in human compared with mouse plasma [9] . A number of mechanisms could potentially account for this observation, including variations in transcriptional and/or translational activation, protein modification, stability and differences in the efficiency of substrate hydrolysis by each orthologue. We previously reported key roles for members of the Sp family of transcription factors in the transcriptional regulation of human and mouse PAF-AH [10] . Our results suggested similar, albeit not identical, transcriptional regulation of these genes [10, 11] . These observations suggest that mechanisms other than promoter-mediated regulatory events probably account for the observed differences in plasma activity levels [9] . In the present study, we found evidence indicating that residues located at N-and C-terminal regions play key roles in the determination of protein expression levels. Our studies unveil novel information related to the mechanisms that control expression of plasma PAF-AH, a phospholipase A 2 with important, but incompletely characterized, roles in physiological and pathological inflammation.
EXPERIMENTAL
Materials
[acetyl-
3 H]PAF was purchased from Amersham Biosciences and unlabelled PAF was from Avanti Polar Lipids. Pfu was from Stratagene and dNTPs, Taq polymerase and a cDNA synthesis kit were purchased from Fermentas Inc. Horseradish peroxidase-labelled secondary antibodies were from BioSource International. The mammalian expression vector pcDNA 3.1 Zeo − , Lipofectamine TM Reagent, and TRIzol ® were purchased from Invitrogen. Applied Biosystems/Ambion provided the PROTEINscript ® II T7 Kit. PVDF membranes and chemiluminescence detection reagents were from PerkinElmer Life Sciences. Protein content was assessed using a Pierce protein assay kit. ICN provided an anti-β-actin mouse monoclonal antibody and cell lysis buffer (E3971) was purchased from Promega Corporation. All other reagents were from Sigma-Aldrich.
Abbreviations used: apoB100, apolipoprotein B100; FBS, fetal bovine serum; PAF, platelet-activating factor; PAF-AH, PAF acetylhydrolase. 1 To whom correspondence should be addressed (email diana.stafforini@hci.utah.edu).
Generation of chimaeric and mutant cDNAs
Site-directed mutagenesis was performed by a two-step amplification protocol using Pfu as previously described [9, 12] . A FLAG tag was inserted at the N-terminal and/or C-terminal ends to allow detection by immunoblot analyses. The products were cloned into the XbaI and KpnI sites of pcDNA 3.1 Zeo − or a bacterial expression vector as previously described [12] . Plasmid DNA was purified using a miniprep purification kit (Qiagen).
Cellular studies
COS-7, HT-29, HCT-116 and PC-3 cells were maintained at 37
• C in a 5% CO 2 atmosphere, using McCoy's medium supplemented with sodium pyruvate and 10 % (v/v) FBS (fetal bovine serum). The day before transfection, we seeded six-well plates at a density of 2-4 × 10 5 cells/well and the following day we transfected 1 μg of each plasmid DNA using Lipofectamine TM . We harvested the cells in 200-400 μl of cell lysis buffer (20 mM Tris/HCl, pH 7.5, 150 mM NaCl, 1 mM Na 2 EDTA, 1 % Triton X-100, 2.5 mM sodium pyrophosphate, 1 mM β-glycerophosphate, 1 mM Na 3 VO 4 and 1 μg/ml leupeptin) or Promega Lysis Buffer, and subjected protein extracts to electrophoresis, as described below. We inhibited cellular protein with 10 μg/ml cycloheximide. RNA synthesis was inhibited by supplementation of 5 μg/ml actinomycin D. We subjected protein extracts (up to 120 μg) to electrophoresis and immunoblot analyses, as previously described [9] . PAF-AH activity was determined by our previously described radiometric assay [13] .
In vitro transcription/translation
We subjected 250 ng of plasmids harbouring various FLAGtagged constructs in pcDNA 3.1 Zeo − to in vitro transcription using a PROTEINscript ® II T7 Kit, following recommendations provided by the manufacturer. The volume was adjusted to 5 μl and the incubation took place for 60 min at 30
• C. Transcription products (2 μl) were immediately subjected to in vitro translation in a total volume of 50 μl. Aliquots (7 μl) were removed at various times (0-30 min) following incubation at 30
• C. We determined PAF-AH activity in the resulting products and subjected aliquots to immunoblot analyses.
RNA isolation, reverse transcription and amplification
For studies that required assessment of mRNA levels, we treated each 35 mm-diameter well with 1 ml of TRIzol ® , and harvested total RNA following recommendations provided by the manufacturer. The samples were treated with DNase to digest contaminating genomic DNA. We then subjected 1 μg of DNA-free RNA to reverse transcription using a first strand cDNA synthesis kit and oligo(dT) 18 primers. The products then were diluted and amplified using primers specific for PAF-AH, β-actin and/or 18S ribosomal RNA. The primers utilized were: human PAF-AH forward: 5 -AAGTCTTGGCTCTTCCTT-AG-3 ; human PAF-AH reverse: 5 -CGTGGTACCTAATTGTA-TTTCTCTATTCCTGAAGAG-3 ; mouse PAF-AH forward: 5 -AGGTCTTGGCTTTTCCTGAG-3 ; mouse PAF-AH reverse: 5 -CGTGGTACCTAATTCTGGGTCTGTGATCCTGG-3 . Amplification took place by denaturation (94
• C for 30 s) followed by 26 cycles of denaturation, annealing and elongation (94
• C for 10 s; 50
• C for 20 s; and 72
• C for 30 s).
Statistics
Immunoblot and enzymatic activity data presented are representative of at least three independent analyses conducted using similar experimental conditions. Enzymatic activity and protein determination assays were conducted in duplicate and the results typically varied by no more than 5 %. The data reported depict the means + − S.D. of representative experiments.
RESULTS
Increased expression of mouse compared with human PAF-AH is determined by the coding sequence and is independent of secretory events
We first hypothesized that natural differences in plasma PAF-AH levels [9] were due to regulatory events determined by the coding sequence. To approach this issue, we assessed whether differential expression was recapitulated following mammalian transfection of individual cDNAs under the control of a common promoter. We transfected COS-7 cells with FLAG-tagged, fulllength human and mouse cDNAs and, 48 h later, harvested the conditioned medium and obtained lysates from transfected cells. The full-length mouse construct resulted in much higher levels of secreted and intracellular PAF-AH activity and protein compared with the human cDNA ( Figures 1A and 1B , left panels).
To assess whether the mechanisms accounting for increased expression of mouse compared with human PAF-AH required active secretion to the extracellular compartment, we expressed truncated products of human and mouse cDNAs that started at Ile 42 and Leu 41 respectively. These constructs lacked the signal for secretion [14] and, as expected, resulted in almost no secretion of PAF-AH protein or enzymatic activity ( Figure 1A , right panel). Analysis of PAF-AH expression in cellular lysates revealed that the large species-specific differences in expression were retained by the truncated constructs ( Figure 1B, right panel) . These results demonstrated that differential expression was independent of secretory events and did not require expression of the N-terminal 40-41 amino acids. Thus the remaining studies were conducted using the truncated form of each orthologue.
To investigate whether our findings were recapitulated in other mammalian cells, we transfected human colon cancer cells (HT-29 and HCT-116), human prostate cancer cells (LNCaP and PC-3) and HEK-293 (human embryonic kidney 293) cells with FLAG-tagged PAF-AH orthologues. We found similar qualitative responses in these cells compared with COS-7 cells (see Supplementary Figure S1 at http://www.BiochemJ. org/bj/428/bj4280269add.htm and results not shown). These results established that our observations were common to multiple mammalian cells and they defined a useful approach that we subsequently utilized to dissect the mechanism(s) leading to enhanced expression of mouse compared with human PAF-AH.
Differences in catalytic efficiency do not contribute to differential PAF-AH expression
We next investigated whether species-specific differences in PAF-AH expression represented intrinsic protein features that conferred the mouse orthologue with higher efficiency of substrate hydrolysis per enzyme molecule. To investigate this, we determined PAF-AH activity in lysates of COS-7 cells transfected with human and mouse cDNAs, and then subjected equal amounts of enzymatic activity to immunoblot analyses. This normalization revealed that the rodent and human enzymes hydrolysed PAF with similar efficiencies (Figure 2A ). We obtained comparable results when we used extracts from BL-21 Escherichia coli cells transformed with the human and mouse cDNAs ( Figure 2B ). The − , full-length human, or full-length mouse PAF-AH cDNAs that harboured a FLAG tag at the C-terminal end. The cells were cultured in 35-mm wells for 48 h following addition of DNA, using 1 ml of culture medium containing 10 % FBS. Aliquots of the conditioned medium were subjected to PAF-AH activity determinations and immunoblot analyses, as described in the Experimental section. The right panel shows identical studies conducted with human and mouse PAF-AH cDNAs that started at Ile 42 and Leu 41 respectively, and that harboured a C-terminal FLAG tag. (B) Transfected cells from (A) were washed three times with PBS and then lysed using 400 μl of lysis buffer. Supernatants containing solubilized proteins were analysed as above. Protein content was assessed as described in the Experimental section.
apparent size of mouse PAF-AH (50 kDa) was higher than that of the human orthologue (46 kDa) despite the fact that the sequence of the cDNAs predicted expression of proteins of similar size (46.5 and 47.5 kDa for mouse and human PAF-AH respectively). However, the fact that we observed similar results in mammalian and bacterial expression systems suggests that mammalian posttranslational modifications did not account for the observed differences in size.
Swapping sequences comprising mouse and human amino acids 41-99 and 42-100 respectively, reveals a distinct role for this region in defining protein expression levels Our next goal was to assess the feasibility of utilizing chimaeric constructs to identify domains that contributed to the regulation of PAF-AH expression. We aligned the cDNA and amino acid sequences of mouse and human PAF-AH orthologues and found that the largest sequence differences were clustered at the N-and C-termini (Table 1) . We initially focused our attention on the Nterminal end. We took advantage of cDNA regions that encoded a stretch of amino acids (WIPNKEYF) completely conserved between the orthologues and that included a unique BamHI restriction site ( Figure 3A) . Replacement of human residues 42-100 with mouse amino acids 41-99 (construct m 41−99 H) dramatically increased protein and enzymatic activity expression ( Figure 3B ). Conversely, when we engineered the mouse cDNA so that its N-terminal residues were replaced with the equivalent human sequences (construct h 42−100 M), the levels of expression significantly decreased ( Figure 3B ). These results established a role for mouse and human residues 41/42-99/100 as key determinants of protein expression levels. The results also suggest that another domain(s) probably played regulatory roles, as the h 42−100 M construct was more efficiently expressed than wild-type human PAF-AH ( Figure 3B ).
Figure 2 Higher expression of mouse compared with human PAF-AH is not due to variations in catalytic efficiency
(A) Extracts from COS-7 cells transfected with FLAG-tagged human or mouse PAF-AH cDNAs that started at Ile 42 or Leu 41 respectively, were subjected to PAF-AH activity determinations (results not shown). Then, aliquots harbouring equal amounts of enzymatic activity (ranging from 25-250 pmol of PAF hydrolysed/min) from each set of transfected cells were subjected to electrophoresis and immunoblotting using anti-FLAG antibodies, as described in the Experimental section. (B) Extracts from E. coli cells transformed with FLAG-tagged human or mouse PAF-AH cDNAs were subjected to PAF-AH activity determinations. Aliquots harbouring equal amounts of enzymatic activity (ranging from 150-900 pmol of PAF hydrolysed/min) were analysed as in (A). − , FLAG-tagged h 42−100 M, m 41−99 H, wild-type human or wild-type mouse PAF-AH cDNAs. The cells were harvested 48 h after transfection, and aliquots harbouring the amounts of protein indicated (1 or 100 μg) were subjected to electrophoresis and immunoblotting, using anti-FLAG and anti-β-actin antibodies. The blot was exposed for short and long periods of time (1 min and 1 h) to allow detection of less abundantly expressed FLAG-tagged proteins. PAF-AH activity and protein levels were determined as described in the Experimental section. 
Definition and characterization of minimal N-terminal regulatory domain
To identify the minimal N-terminal sequence required for regulation of protein levels, we expressed chimaeric PAF-AH constructs in which the N-terminal end was progressively altered to include increasing proportions of the mouse cDNA (Figure 4) . We expressed these chimaeras and found maximal increases in activity and protein levels by replacing human residues 42-100 with mouse amino acids 41-99 (Figure 4) . Inclusion of additional residues dramatically decreased expression, possibly owing to decreased stability and/or a peculiar conformation adopted by the resulting chimaeric construct. To assess whether mouse amino acids 71-99 were sufficient for enhanced expression, we tested a chimaeric protein in which this stretch of the mouse cDNA replaced the corresponding human amino acids. This construct and the human wild-type cDNA were expressed with similar efficiencies (results not shown). Thus the entire stretch comprising residues 41-99 was required for enhanced expression.
We next evaluated whether the striking effects of mouse residues 41-99 on protein expression were due to posttranslational modification(s) unique to one of the orthologues. We compared mouse and human stretches comprising residues 41-99 and 42-100 respectively, using online proteomic prediction tools. These analyses revealed the presence of two potential asparagine glycosylation sites (Asn 59 and Asn 75 ) in mouse, but not human, PAF-AH. However, we found that mouse N59Q, N75Q, S61P/P63S mutants and wild-type mouse PAF-AH were expressed at similar levels ( Figure 4B ), suggesting that these sites are not post-translationally modified. In addition, we generated point mutations in other non-conserved regions of both cDNAs and again found similar expression levels (see Supplementary Figure S2 at http://www.BiochemJ. org/bj/428/bj4280269add.htm). These results, combined with the above findings, suggested that a relatively large stretch of amino acids was responsible for effects mediated by the N-terminal end.
Analysis of domains between amino acids 118 and 440 of mouse PAF-AH at the protein level
To investigate the contribution of additional domains to the definition of PAF-AH levels, we utilized previously described chimaeric constructs in which regions of the human cDNA were swapped with corresponding mouse sequences [9] . These constructs were expressed at levels comparable with those observed using the human cDNA ( Figure 5 ). The string comprising mouse residues 338-440, when exchanged with the corresponding human sequences, generated the Hm 338−440 chimaeric construct, the expression level of which was almost 3-fold higher than that of wild-type human PAF-AH ( Figure 5 ). The 22 C-terminal amino acids of this domain were the least conserved in the region ( Figure 6A ). Introduction of this 22-amino acid stretch into the human sequence generated the Hm 419−440 chimaeric construct which was expressed at a level comparable with that of Hm 338−440 ( Figure 6B ). These results suggested that the 22 C-terminal amino acids accounted for most of the enhanced expression mediated by this domain. These combined studies identified a C-terminal region that contributed to the definition of expression levels, but to a much lesser extent than the N-terminal domain. 
Efficiency of transcription and translation and mRNA stability
To identify the mechanism(s) that contributed to the modulation of PAF-AH expression, we determined steady-state levels of human and mouse PAF-AH mRNAs following transfection of COS-7 cells with each cDNA (see Supplementary Figure  S3 at http://www.BiochemJ.org/bj/428/bj4280269add.htm). We detected comparable mRNA levels, suggesting that differences in the efficiency of transcription did not modulate PAF-AH expression. In addition, we compared the rate of mRNA and activity decay following arrest of RNA biosynthesis with actinomycin D. We found a moderate tendency towards higher stability of the human compared with mouse PAF-AH mRNA under these experimental conditions (see Supplementary Figure S4 at http://www.BiochemJ.org/bj/428/bj4280269add.htm). Since neither the efficiency of mRNA synthesis, nor its stability, accounted for differences in protein expression, we assessed whether variations in the rate of protein synthesis contributed to the observed effects. We subjected mouse and human PAF-AH cDNAs to in vitro transcription-translation and then assessed PAF-AH activity and protein levels. We found similar accumulation of mouse compared with human PAF-AH in three independent experiments, suggesting that the observed differences in expression were not due to variations in the translatability of individual mRNAs (see Supplementary Figure  S5 at http://www.BiochemJ.org/bj/428/bj4280269add.htm).
Decay rates of precursor and mature forms of PAF-AH
Our next goal was to investigate whether mouse PAF-AH decayed with slower kinetics compared with the human protein, thus resulting in higher steady-state expression levels. To test this, we assessed enzymatic activity and protein levels in transfected cells treated with cycloheximide to arrest protein biosynthesis. We initially supplemented the inhibitor 24 h following transfection, a time when significant amounts of the proteins had probably progressed to mature, fully active forms. We found that the human orthologue decayed at a slightly higher rate compared with the mouse protein, and that these modest differences were recapitulated at the enzymatic activity level (Figure 7) .
The above experiments evaluated the behaviour of mature forms of PAF-AH that had accumulated following relatively prolonged transfection periods. Our next goal was to study the efficiency with which precursors were processed to mature proteins. To assess this, we supplemented cycloheximide at various times shortly after cDNA transfection. Pilot experiments demonstrated that addition of the inhibitor 6 h following transfection allowed sufficient synthesis of PAF-AH for detection purposes and also revealed important differences between the orthologues. Following early arrest of protein synthesis, human PAF-AH protein was rapidly degraded, and enzymatic activity remained constant ( Figure 8A , left panel). These results suggested that a large portion of immunoreactive precursors were inactive and short-lived. In contrast, mouse PAF-AH species displayed remarkable stability, and enzymatic activity continued to increase after cycloheximide addition ( Figure 8A, right panel) . The increase in activity probably reflected processing of inactive precursors to fully active protein. Importantly, increased stability of the mouse protein was mediated by mouse N-terminal sequences comprising amino acids 41-99, as introduction of this stretch into the human cDNA dramatically increased protein expression levels ( Figure 8A, centre panel) . In contrast, mouse C-terminal amino acids 419-440 did not affect the kinetics of protein decay compared with the wildtype human protein (results not shown). These results suggested that the mechanism whereby the N-terminal domain of PAF-AH affected protein levels involved modulation of the rate of decay of precursor forms of the protein.
We next investigated whether the effects of mouse N-terminal sequences on steady-state PAF-AH expression ( Figure 4A ) were due to increased stability of precursors, using the approach shown in Figure 8 (A). We found a significantly higher precursor stability when human residues 42-79 were replaced with mouse amino acids 41-78; maximal effects were observed by replacing human residues 42-100 with the corresponding mouse sequences ( Figure 8B ). These results were consistent with those shown in Figure 4 (A) and they suggested that increased stability of PAF-AH precursors accounted for higher steady-state expression levels. Interestingly, the region comprising mouse amino acids 71-99 is predicted to form a globular structure according to recently developed computational tools [15, 16] . In contrast, the corresponding human sequences probably adopt an unstructured, disordered conformation [2, 17] . These folding differences may contribute to the definition of stability of PAF-AH precursor polypeptides before they mature to fully active protein products. Formation of globular structures may be facilitated by the hydrophobic, non-polar nature of mouse compared with human N-terminal residues ( Figure 8C ). In support of this model, we found that the degree of hydrophobicity and polarity of the Nterminal region correlates with the level of PAF-AH expression in human, mouse, rat, dog and bovine plasma (results not shown).
Human and mouse N-terminal domains affect the expression of an unrelated polypeptide
The observed differences in expression could be due to stabilizing effects mediated by mouse N-terminal sequences, de-stabilizing effects due to human sequences, or both. To differentiate among these possibilities, we investigated whether expression of an unrelated protein was affected by inclusion of the sequences identified. We cloned sequences encoding residues 41-99 or
Figure 9 The N-terminal domain of PAF-AH controls expression of a heterologous protein
The top panel is a diagrammatic representation of constructs generated to assess whether domains near the N-termini of human and mouse PAF-AH modulate expression of an unrelated polypeptide. All constructs were FLAG-tagged at both the N-and C-terminal ends and included an internal domain of human apoB100 comprising amino acids 4035-4298. COS-7 cells were transfected with 1 μg of the constructs indicated. The cells were harvested 48 h following transfection and aliquots harbouring 75 μg of total protein were subjected to electrophoresis and immunoblotting (IB) using anti-FLAG and anti-β-actin antibodies (bottom left-hand panel). The blot was exposed for short and long periods of time (1 min and 60 min) to allow detection of less abundantly expressed FLAG-tagged proteins. The bottom right-hand panel shows results obtained following transfection of COS-7 cells with 1 μg of the constructs indicated. The cells were harvested 6, 24 and 48 h following addition of complete growth medium. Aliquots harbouring 35 μg of total protein were subjected to electrophoresis and immunoblotting using anti-FLAG and anti-β-actin antibodies, as described above.
42-100 upstream of an internal region of apoB100 (apolipoprotein B100) comprising amino acids 4035-4298, added FLAG tags, and then expressed the cDNAs in COS-7 cells (Figure 9) . A FLAG-tagged construct harbouring apoB100 residues 4035-4298 served as control. The expression level of a fusion protein harbouring mouse residues 41-99 was much higher than that of the control polypeptide ( Figure 9 , bottom left panel). In contrast, when the study was repeated using the N-terminal human sequences, expression of the fusion protein was highly inhibited. These results were qualitatively similar to those observed using PAF-AH constructs. To test whether the Nterminal domains modulated expression by affecting protein stability, we investigated the kinetics of expression of apoB constructs at various points following transfection. We found evidence supporting a stabilizing role for mouse amino acids 41-99 ( Figure 9 , bottom right panel). In contrast, the N-terminal human sequences destabilized the polypeptide, suggesting that this stretch of human PAF-AH may act as a degron, in a fashion similar to that shown for other proteins [18] .
DISCUSSION
In the present study, we investigated the mechanisms responsible for differences in expression of human and mouse plasma PAF-AH. The biological consequences associated with large variations in the levels of expression remain to be established, but a possibility is that humans may require expression of relatively low enzyme levels owing to the biological compartments in which the enzyme functions. Human PAF-AH associates primarily with low-density lipoprotein particles that provide an optimal environment for substrate hydrolysis [2, 19] . In contrast, the endogenous rodent activity usually associates with high-density lipoproteins in which substrate hydrolysis is less efficient [2, 9, 19, 20] . Thus compensatory mechanisms influenced by the location of each orthologue may have evolved to insure adequate hydrolytic capacities in the plasma of individual species.
Our initial studies revealed that differences in expression were qualitatively recapitulated when several mammalian cells were transfected with human and mouse PAF-AH cDNAs. These constructs were cloned utilizing the same restriction sites of the mammalian expression vector pcDNA 3.1/Zeo − , they included the cytomegalovirus enhancer-promoter, the bovine growth hormone polyadenylation signal, and a transcription termination sequence. In addition, the most important elements that define an optimal AUG context were identical for all constructs, that is, all contained an adenine at position − 3 and a guanine at position + 4. The fact that differences in expression were recapitulated in mammalian cells transfected with human and mouse cDNAs suggested that sequences in the coding region of the gene, or features defined at the protein level, accounted for the observed effects.
Studies focused on the contribution of N-terminal sequences showed that swapping a 90 nt N-terminal domain encoding residues 41-71 of mouse PAF-AH exerted modest detectable enhancement of expression. When the size of the swapped domain was further increased to include residues 41-99, we observed robust increases in protein expression and enzymatic activity. These studies suggested that the domain harbouring amino acids 71-99 could be responsible for enhanced expression. Interestingly, this stretch harbours an unusual cis-peptide bond between Phe 72 and Asp 73 that was deemed to be an outlier in the crystal structure of the human protein [17] . However, a human construct in which amino acids 72-100 were replaced with mouse amino acids 71-99 resulted in expression levels similar to those of wild-type human PAF-AH, suggesting that this stretch was not sufficient for enhanced expression. Moreover, replacement of Asp 73 with glycine did not affect expression levels (Supplementary Figure S2) . These studies provided the first indication that a relatively large protein motif, and not a handful of isolated amino acids, modulated expression levels.
Our studies also showed a similar, albeit much less prominent, role for 22 C-terminal amino acids on the efficiency of protein expression. The recently reported crystal structure of the human isoform points to several disordered residues (A, 426-429; B, 428-429, [17] ) within the C-terminal region we identified (amino acids 419-440). Whether corresponding domains in the mouse and other orthologues adopt a different conformation that increases expression levels is currently unknown. Sequential replacement of the remaining internal human domains with the corresponding mouse sequences always resulted in equal or moderately enhanced levels of expression. Although these results suggest minor contributions from regions additional to those identified in this study, it is also possible that further regulation involves co-operation among two or more domains.
We tested several candidate mechanisms for modulation of PAF-AH expression. Differences in catalytic efficiency did not account for the observed effects, as the rates of PAF hydrolysis per molecule of PAF-AH were comparable. We found similar efficiency of transcription and translation of the cDNAs, and ruled out differences in mRNA stability. In contrast, protein decay studies showed higher stability of precursor forms of mouse versus human PAF-AH. This feature allowed maturation of early precursors to fully functional forms of the enzyme, as shown by our kinetic studies in the presence of cycloheximide. The molecular basis for differential expression seems to be due, at least in part, to the predicted ability of mouse, but not human, Nterminal sequences to form globular structures. Indeed, the mouse PAF-AH N-terminus harbours two highly hydrophobic apolar regions that coincide with those that are essential for enhanced expression. Interestingly, the polarity of N-terminal sequences has previously been shown to affect the folding of other proteins [21] . This feature may also facilitate folding of precursor mouse PAF-AH polypeptides, thus increasing their stability. Conversely, the presence of disordered structures at the N-terminus of human PAF-AH may attenuate the stability of early precursors, and decrease steady-state expression levels. It has been previously noted that the distribution of residues along a polypeptide chain is a strong determinant of both secondary and tertiary structure within proteins [22] . In particular, clustering of hydrophobic residues to form a rudimentary core may induce the formation and stabilization of structures before highly specific side-chain contacts develop [23] . Additional evidence to support this model came from studies showing that fusion of the mouse domain to a heterologous protein increased its steady-state expression levels. Conversely, the corresponding stretch of sequences derived from human PAF-AH had a destabilizing effect. These studies served to demonstrate that the identified N-terminal stretches in PAF-AH orthologues have opposite effects on expression.
In summary, we have discovered that mouse PAF-AH is more efficiently expressed in mammalian cells and in plasma than the human orthologue. The differences are defined by Nand, to a much lesser extent, C-terminal sequences unique to each orthologue. Folding of the N-terminal domains appears to modulate expression levels by affecting the stability of precursor polypeptides during biosynthesis. These findings provide new understanding of the mechanisms that account for differences in expression of PAF-AH in mammals.
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Figure S4 Variations in mRNA stability do not account for differential expression of PAF-AH
(A) COS-7 cells were transfected with 1 μg of FLAG-tagged human or mouse PAF-AH cDNAs. Untransfected cells served as negative controls. After 48 h, we replaced the culture medium with fresh medium supplemented with actinomycin D (ACTD, 5 μg/ml). The cells were cultured for 0-22 h at 37 • C and then harvested, as above. PAF-AH activity and protein levels were determined as described in the Experimental section in the main paper. (B) Total RNA was isolated from COS-7 cells transfected as above. The samples were treated with DNase, and the DNA-free RNA then was subjected to reverse transcription, as described in the Experimental section. Aliquots of the resulting cDNAs were amplified using PAF-AH-and 18S rRNA-specific primers. Untransfected (UnTr) cells were subjected to the same procedure, and served as negative controls. The amplification products were subjected to electrophoresis on 1.5 % agarose gels and the products were visualized with ethidium bromide.
